94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Toxicol.
Sec. Computational Toxicology and Informatics
Volume 7 - 2025 | doi: 10.3389/ftox.2025.1564864
This article is part of the Research TopicApplication of New Approach Methodologies in Toxicological Assessment of Next Generation Tobacco and Nicotine ProductsView all 3 articles
Quantitative adverse outcome pathway modeling for cigarette smoke-inducible airway mucus hypersecretion. Part 2: Bayesian network modeling for probabilistic risk estimation
Provisionally accepted- Japan Tobacco (Japan), Tokyo, Japan
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The development of in vitro tests that reproduce real-world situations is crucial for toxicity-and disease-risk assessment without animal testing. Because signs and symptoms of health concerns can be complex, it is helpful to create a simplified representation of such manifestations using a conceptual framework such as an adverse outcome pathway (AOP). Combining an AOP with computational models could be a potential tool for the extrapolation of in vitro results to real-world scenarios. Here, we applied Bayesian network-based probabilistic quantitative models for disease-related risk estimation using an in vitro dataset on the AOP of mucus hypersecretion-a known representative symptom of chronic airway disease-obtained by repeated exposure of human bronchial epithelial cells to whole cigarette smoke. We also used a computational aerosol dosimetry model to account for differences between in vitro exposure concentrations and human exposure scenarios. The results revealed dose-and exposure repetition-dependent increases in adverse outcome probability, suggesting that the model reflects the risk continuum of cigarette smoking. Furthermore, under certain assumptions, dosimetry modeling indicated that our in vitro exposure concentrations were similar to actual smoking scenarios. As an exercise, we also calculated in vitro odds ratios for chronic bronchitis that were comparable to the range of real-world odds ratios for chronic bronchitis due to cigarette smoking. Our combinatory risk-assessment approach could be a valuable tool for estimating the chronic inhalation effects of inhalable products and chemicals.
Keywords: qAOP modeling, chronic bronchitis, repeated exposure, Inhalation, New approach methodology
Received: 22 Jan 2025; Accepted: 21 Mar 2025.
Copyright: © 2025 Ito, Ichikawa, Matsumoto, Muratani, Sano, Mori and Erami. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Shigeaki Ito, Japan Tobacco (Japan), Tokyo, Japan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.